Fol. Biol. 2015, 61, 195-202
https://doi.org/10.14712/fb2015061050195
Triptolide Induces Apoptosis and Synergizes with Cisplatin in Cisplatin-Resistant HNE1/DDP Nasopharyngeal Cancer Cells
References
1. 2014) Sorafenib and triptolide as combination therapy for hepatocellular carcinoma. Surgery 156, 270-279.
< , O. A., Sangwan, V., Banerjee, S., Krosch, T. C., Chugh, R., Saluja, A., Vickers, S. M., Jensen, E. H. (https://doi.org/10.1016/j.surg.2014.04.055>
2. 2012) Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am. J. Pathol. 180, 2491-2503.
< , L. L., Hazari, S., Mehra, S., M., Kaushal, D., Moroz, K., Dash, S. (https://doi.org/10.1016/j.ajpath.2012.02.024>
3. 2014). The mitochondrial permeability transition pore and cancer: molecular mechanisms involved in cell death. Front. Oncol. 4, 302.
< , M., Pinton, P. (https://doi.org/10.3389/fonc.2014.00302>
4. 2013) Triptolide, a Chinese herbal extract, enhances drug sensitivity of resistant myeloid leukemia cell lines through downregulation of HIF-1α and Nrf2. Pharmacogenomics 14, 1305-1317.
< , F., Liu, Y., Wang, S., Guo, X., Shi, P., Wang, W., Xu, B. (https://doi.org/10.2217/pgs.13.122>
5. 2010) Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells through a ROS-dependent mechanism. Biochem. Pharmacol. 79, 350-360.
< , D., Gao, X., Jiang, H., Janic, B., Arbab, A. S., Rojanasakul, Y., Dulchavsky, S. A, Gautam, S. C. (https://doi.org/10.1016/j.bcp.2009.09.006>
6. 2014) MTA1 overexpression induces cisplatin resistance in nasopharyngeal carcinoma by promoting cancer stem cells properties. Mol. Cells 37, 699-704.
< , X., Zhang, Q., Xia, S., Zhang, Y., Deng, X., Su. W., Huang, J. (https://doi.org/10.14348/molcells.2014.0029>
7. 2015) Synergistic antitumor effect of triptolide and cisplatin in cisplatin resistant human bladder cancer cells. J. Urol. 193, 1016-1022.
< , J. N., Byun, S.S., Lee, S., Oh, J. J., Hong, S. K., Lee, S. E., Yeon, J. S. (https://doi.org/10.1016/j.juro.2014.09.007>
8. 2011) Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Biochim. Biophys. Acta 1807, 735-745.
< , I. R., Tufo, G., Pervaiz, S., Brenner, C. (https://doi.org/10.1016/j.bbabio.2011.03.010>
9. 2012) Synergistic anticancer activity of triptolide combined with cisplatin enhances apoptosis in gastric cancer in vitro and in vivo. Cancer Lett. 319, 203-213.
< , C., Chu, C.-Y., Huang L.-H., Wang, M. H., Sheu, L. F., Yeh, J. I., Hsu, H. Y. (https://doi.org/10.1016/j.canlet.2012.01.006>
10. 2014) Triptolide: Progress on research in pharmacodynamics and toxicology. J. Ethnopharmacol. 155, 67-79.
< , X. J. Y., Jiang, Z. Z., Zhang, L. Y. (https://doi.org/10.1016/j.jep.2014.06.006>
11. 2011) Triptolide and its expanding multiple pharmacological functions. Int. Immunopharmacol. 11, 377-383.
< , Q. Y. (https://doi.org/10.1016/j.intimp.2011.01.012>
12. 2012) The role of miRNAs and EBV BARTs in NPC. Semin. Cancer Biol. 22, 166-172.
< , A. R., Raab-Traub, N. (https://doi.org/10.1016/j.semcancer.2011.12.001>
13. 2013) Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways. Oncogene 32, 2756-2766.
< , Y., Zhang, Q., Atsaves, V., Yang, H., Claret, F. X. (https://doi.org/10.1038/onc.2012.294>
14. 2013) Thioredoxin-mediated redox regulation of resistance to endocrine therapy in breast cancer. Biochim. Biophys. Acta 1836, 60-79.
, R. B., Roy, D. (
15. 2014). The mitochondrial permeability transition pore and its adaptive responses in tumor cells. Cell Calcium 56, 437-445.
< , A., Bernardi, P. (https://doi.org/10.1016/j.ceca.2014.10.003>
16. 2013) Oxidative stress and cancer: an overview. Ageing Res. Rev. 12, 76-90.
< , V., Moline, T., Somoza, R., Paciucci, R., Kondoh, H., Leonart, M. E. (https://doi.org/10.1016/j.arr.2012.10.004>
17. 2014) Chronic treatment with cisplatin induces replication-dependent sister chromatid recombination to confer cisplatin-resistant phenotype in nasopharyngeal carcinoma. Oncotarget 5, 6323-6237.
< , W. P., Hsu, S. H., Wu, C. K., Chang, S. B., Lin, Y. J., Yang, W. B., Hung, J. J., Chiu, W. T., Tzeng, S. F., Tseng, Y. L., Chang, J. Y., Su, W. C., Liaw, H. (https://doi.org/10.18632/oncotarget.2210>
18. 2014) Cisplatin combined with metformin inhibits migration and invasion of human nasopharyngeal carcinoma cells by regulating E-cadherin and MMP-9. Asian Pac. J. Cancer Prev. 15, 4019-4023.
< , X. J., Zhang, P., Li, H. H., Jiang, Z. W., Jiang, C. C., Liu, H. (https://doi.org/10.7314/APJCP.2014.15.9.4019>
19. 2013) Role of oxidative stress, endoplasmic reticulum stress and ERK activation in triptolideinduced apoptosis. Int. J. Oncol. 42, 1605-4612.
< , B. J., Chiu, G. N. (https://doi.org/10.3892/ijo.2013.1843>
20. 2010) Altered mitochondrial membrane potential, mass, and morphology in the mononuclear cells of humans with type 2 diabetes. Transl. Res. 156, 15-25.
< , M. E., Wang, J. L., Shenouda, S. M., Hagen, T. M., Smith, A. R., Kizhakekuttu, T. J., Kluge, M. A., Weihrauch, D., Gutterman, D. D., Vita, J. A. (https://doi.org/10.1016/j.trsl.2010.04.001>
21. 2014). Silencing SATB1 influences cell invasion, migration, proliferation, and drug resistance in nasopharyngeal carcinoma. Int. J. Clin. Exp. Pathol. 7, 914-922.
, C. S., Zhou, D. N., Yang, Q. Q., Deng, Y. (
22. 2013) Triptolide avoids cisplatin resistance and induces apoptosis via the reactive oxygen species/nuclear factor-κB pathway in SKOV3 platinum-resistant human ovarian cancer cells. Oncol. Lett. 6, 1084-1092.
< , Y. Y., Chen, H. P., Tan, B. Z., Yu, H. H., Huang, X. S. (https://doi.org/10.3892/ol.2013.1524>
23. 2011) Loperamide, an FDA-approved antidiarrhea drug, effectively reverses the resistance of multidrug resistant MCF-7/MDR1 human breast cancer cells to doxorubicin- induced cytotoxicity. Cancer Invest. 30, 119-125.
< , Y. F., Sridhar, R., Shan, L., Sha, W., Gu, X., Sukumar, S. (https://doi.org/10.3109/07357907.2011.640653>
24. 2012) Triptolide cooperates with cisplatin to induce apoptosis in gemcitabine-resistant pancreatic cancer. Pancreas 41, 1029-1038.
< , W., Li, J., Wu, S., Li, S., Le, L., Su, X., Qiu, P., Hu, H., Yan, G. (https://doi.org/10.1097/MPA.0b013e31824abdc0>